232 related articles for article (PubMed ID: 31502889)
1. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review.
Bonacho T; Rodrigues F; Liberal J
Biotech Histochem; 2020 Feb; 95(2):71-91. PubMed ID: 31502889
[TBL] [Abstract][Full Text] [Related]
2. The role of immunohistochemistry in the differential diagnosis of breast lesions.
Moriya T; Kozuka Y; Kanomata N; Tse GM; Tan PH
Pathology; 2009 Jan; 41(1):68-76. PubMed ID: 19089742
[TBL] [Abstract][Full Text] [Related]
3. New trends of immunohistochemistry for making differential diagnosis of breast lesions.
Moriya T; Kasajima A; Ishida K; Kariya Y; Akahira J; Endoh M; Watanabe M; Sasano H
Med Mol Morphol; 2006 Mar; 39(1):8-13. PubMed ID: 16575508
[TBL] [Abstract][Full Text] [Related]
4. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
Collins LC; Carlo VP; Hwang H; Barry TS; Gown AM; Schnitt SJ
Am J Surg Pathol; 2006 Aug; 30(8):1002-7. PubMed ID: 16861972
[TBL] [Abstract][Full Text] [Related]
5. Use of immunohistochemistry in the diagnosis of problematic breast lesions.
Lee AH
J Clin Pathol; 2013 Jun; 66(6):471-7. PubMed ID: 23486609
[TBL] [Abstract][Full Text] [Related]
6. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin.
Dabbs DJ; Bhargava R; Chivukula M
Am J Surg Pathol; 2007 Mar; 31(3):427-37. PubMed ID: 17325485
[TBL] [Abstract][Full Text] [Related]
7. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
8. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
Rabban JT; Chen YY
Hum Pathol; 2008 Feb; 39(2):175-83. PubMed ID: 18206495
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
Popnikolov NK; Cavone SM; Schultz PM; Garcia FU
Mod Pathol; 2005 Dec; 18(12):1535-41. PubMed ID: 16258511
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin immunohistochemistry in breast pathology: uses and pitfalls.
Canas-Marques R; Schnitt SJ
Histopathology; 2016 Jan; 68(1):57-69. PubMed ID: 26768029
[TBL] [Abstract][Full Text] [Related]
12. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
[TBL] [Abstract][Full Text] [Related]
13. The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions.
Pavlakis K; Messini I; Vrekoussis T; Yiannou P; Keramopoullos D; Louvrou N; Liakakos T; Stathopoulos EN
BMC Cancer; 2008 Apr; 8():88. PubMed ID: 18384688
[TBL] [Abstract][Full Text] [Related]
14. Increased N-myc downstream-regulated gene 1 expression is associated with breast atypia-to-carcinoma progression.
Mao XY; Fan CF; Wei J; Liu C; Zheng HC; Yao F; Jin F
Tumour Biol; 2011 Dec; 32(6):1271-6. PubMed ID: 21909787
[TBL] [Abstract][Full Text] [Related]
15. D2-40: an additional marker for myoepithelial cells of breast and the precaution in interpreting tumor lymphovascular invasion.
Ren S; Abuel-Haija M; Khurana JS; Zhang X
Int J Clin Exp Pathol; 2011 Jan; 4(2):175-82. PubMed ID: 21326813
[TBL] [Abstract][Full Text] [Related]
16. Spindle cell ductal carcinoma in situ. An unusual variant of ductal intra-epithelial neoplasia that simulates ductal hyperplasia or a myoepithelial proliferation.
Farshid G; Moinfar F; Meredith DJ; Peiterse S; Tavassoli FA
Virchows Arch; 2001 Jul; 439(1):70-7. PubMed ID: 11499843
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.
Hilson JB; Schnitt SJ; Collins LC
Am J Surg Pathol; 2009 Feb; 33(2):227-32. PubMed ID: 18936688
[TBL] [Abstract][Full Text] [Related]
18. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of E-cadherin in lobular carcinomas of the breast.
Da Silva L; Parry S; Reid L; Keith P; Waddell N; Kossai M; Clarke C; Lakhani SR; Simpson PT
Am J Surg Pathol; 2008 May; 32(5):773-83. PubMed ID: 18379416
[TBL] [Abstract][Full Text] [Related]
20. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW
J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
